Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above

NCT ID: NCT05382871

Last Updated: 2023-06-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 1804 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-27
• Study Completion Date: 2024-03-31

Brief Summary

This trial adopts a randomized, double-blind and positive control design, it is planned to recruit 1800 healthy participants who have been vaccinated with 2/3 doses of COVID-19 inactivated vaccine or mRNA vaccine for 3 months. The participants will be divided into two strata according to the types of vaccines administered, including 900 participants of COVID-19 inactivated vaccine and 900 participants of mRNA vaccine. According to the ratio of 1:1:1, each stratum was randomly assigned to three groups: sequential BIBP- COVID-19 inactivated vaccine (Omicron), WIBP-COVID-19 inactivated vaccine (Omicron) or COVID-19 inactivated vaccine (prototype strain). And according to D0, D28 immunization schedule, two doses of corresponding group vaccines are sequentially administered.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

1: BIBP Inactivated COVID-19 vaccine (Omicron)

subjects will be blinded and receive two doses of BIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine

Group Type: EXPERIMENTAL

BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)

Intervention Type: BIOLOGICAL

intramuscular injection in the deltoid muscle

2: WIBP Inactivated COVID-19 vaccine (Omicron)

subjects will be blinded and receive two doses of WIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine

Group Type: EXPERIMENTAL

WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)

Intervention Type: BIOLOGICAL

intramuscular injection in the deltoid muscle

3：BIBP Inactivated COVID-19 vaccine (Omicron)

subjects will be blinded and receive two doses of BIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine

Group Type: EXPERIMENTAL

BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)

Intervention Type: BIOLOGICAL

intramuscular injection in the deltoid muscle

4: WIBP Inactivated COVID-19 vaccine (Omicron)

subjects will be blinded and receive two doses of WIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine

Group Type: EXPERIMENTAL

WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)

Intervention Type: BIOLOGICAL

intramuscular injection in the deltoid muscle

5：Inactivated COVID-19 Vaccine (prototype)

subjects will be blinded and receive two doses of Inactivated COVID-19 Vaccine (prototype) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine

Group Type: ACTIVE_COMPARATOR

COVID-19 Vaccine (Vero Cell), Inactivated

Intervention Type: BIOLOGICAL

intramuscular injection in the deltoid muscle

6：Inactivated COVID-19 Vaccine (prototype)

subjects will be blinded and receive two doses of Inactivated COVID-19 Vaccine (prototype) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine

Group Type: ACTIVE_COMPARATOR

COVID-19 Vaccine (Vero Cell), Inactivated

Intervention Type: BIOLOGICAL

intramuscular injection in the deltoid muscle

Interventions

BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)

intramuscular injection in the deltoid muscle

Intervention Type: BIOLOGICAL

WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)

intramuscular injection in the deltoid muscle

Intervention Type: BIOLOGICAL

COVID-19 Vaccine (Vero Cell), Inactivated

intramuscular injection in the deltoid muscle

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age range: populations aged 18 years and above.
• Judged by the investigator that the health condition is well after inquiry and physical examination.
• Vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine or mRNA vaccine for ≥ 3 months.
• Female participants who are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 7 months after enrollment. Effective contraceptive measures have been taken within 2 weeks before inclusion.
• During the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan.
• With self ability to understand the study procedures, the informed consent & voluntarily sign an informed consent form and is able to comply with the requirements of the clinical study protocol.

Exclusion Criteria

• Confirmed cases, suspected cases or asymptomatic cases of COVID-19;
• With a history of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (self-report, on-site inquiry);
• Has vaccinated with one or four doses and above COVID-19 vaccine;
• Axillary temperature ≥37.3℃ (Tympanic temperature ≥ 37.6 ℃);
• Previous allergic reactions to drug or vaccination (such as acute allergic reactions, urticaria, eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known components of COVID-19 vaccine (self-report, onsite enquiry);
• Have a history of hospital-diagnosed thrombocytopenia or other coagulation disorders (self-report, onsite enquiry);
• With known immunological impairment or immunocompromised diagnosed by the hospital (self-report, onsite enquiry);
• Have an uncontrolled epilepsy and other progressive neurological diseases or a history of Guillain-Barre syndrome (self-report, onsite enquiry);
• Received whole blood, plasma and immunoglobulin therapy within 1 month (self-report, onsite enquiry);
• Known or suspected severe illness includes: respiratory illness, acute infection or active attacks of chronic illness, liver and kidney disease, severe diabetes mellitus, malignant tumor, infectious or allergic skin disease, Human Immunodeficiency Virus (HIV) infection (self-report, onsite enquiry, provide test report if available);
• With hospital-diagnosed serious cardiovascular diseases (cardiopulmonary failure, drug-uncontrolled hypertension (physical examination of systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg), acute attacks of chronic respiratory illness (self-report, onsite enquiry);
• Received live attenuated vaccines within 1 month before vaccination (self-report, onsite enquiry);
• Received inactivated vaccines within 14 days before vaccination (self-report, onsite enquiry);
• Participating or planning to participate in other interventional vaccine clinical trials during this study
• Other vaccination-related contraindications considered by investigators.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

Sponsor Role: collaborator

Wuhan Institute of Biological Products Co., Ltd

INDUSTRY

Sponsor Role: collaborator

The University of Hong Kong

OTHER

Sponsor Role: collaborator

China National Biotec Group Company Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ivan Hung, Clinical Professor

Role: PRINCIPAL_INVESTIGATOR

The University of Hong Kong

Locations

Queen Mary Hospital

Hong Kong, , Hong Kong

Countries

Hong Kong

Other Identifiers

CNBG-O-2022002

Identifier Type: -

Identifier Source: org_study_id